Literature DB >> 8576843

Determination of protein binding by in vitro charcoal adsorption.

J Yuan1, D C Yang, J Birkmeier, J Stolzenbach.   

Abstract

Certain compounds such as SC-52151 have extensive nonspecific adsorption to the ultrafiltration devices or to dialysis membranes and therefore can not be measured by the conventional ultrafiltration or equilibrium dialysis methods. A new method based on charcoal adsorption was developed to overcome this difficulty. Unlike many conventional methods, which are based on the separation of free drug from bound drug under equilibrium conditions, the new method is operated under nonequilibrium conditions and involves measuring the time course of decline of the percentage of bound drug remaining in plasma while the free drug is being removed by charcoal adsorption. Theoretical aspects of the method and the data processing procedure are presented. SC-98A, a compound with minimal nonspecific adsorption to the ultrafiltration membrane, was used to demonstrate the applicability of this method against the ultrafiltration method. Using this method, the protein binding of SC-52151 in human plasma at 1.0 microgram/ml was determined to be in the range of 91.4-97.7% at room temperature.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8576843     DOI: 10.1007/bf02353785

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  12 in total

1.  Kinetic approach to drug-protein binding.

Authors:  J S Robertson; B W Madsen
Journal:  J Pharm Sci       Date:  1974-02       Impact factor: 3.534

2.  A new method for the measurement of dissociation rates for complexes between small ligands and proteins as applied to the palmitate and bilirubin complexes with serum albumin.

Authors:  A Svenson; E Holmer; L O Andersson
Journal:  Biochim Biophys Acta       Date:  1974-03-14

3.  Dynamic dialysis as a method for studying protein binding. II. Evaluation of the method with a number of binding systems.

Authors:  M C Meyer; D E Guttman
Journal:  J Pharm Sci       Date:  1970-01       Impact factor: 3.534

4.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

5.  Determination of non-albumin-bound bilirubin in human serum.

Authors:  J Jacobsen; O Fedders
Journal:  Scand J Clin Lab Invest       Date:  1970-11       Impact factor: 1.713

6.  Evaluation of methods to determine protein-binding of drugs. Equilibrium dialysis, ultrafiltration, ultracentrifugation, gel filtration.

Authors:  H Kurz; H Trunk; B Weitz
Journal:  Arzneimittelforschung       Date:  1977-07

7.  Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere.

Authors:  D P Getman; G A DeCrescenzo; R M Heintz; K L Reed; J J Talley; M L Bryant; M Clare; K A Houseman; J J Marr; R A Mueller
Journal:  J Med Chem       Date:  1993-01-22       Impact factor: 7.446

8.  Some limitations of using equilibrium dialysis to study human serum albumin-testosterone interaction.

Authors:  G W Moll; R L Rosenfield
Journal:  J Clin Endocrinol Metab       Date:  1978-03       Impact factor: 5.958

9.  Ultrafiltration in serum protein binding determinations.

Authors:  J B Whitlam; K F Brown
Journal:  J Pharm Sci       Date:  1981-02       Impact factor: 3.534

10.  Protein binding of tirilazad (U-74006) in human, Sprague-Dawley rat, beagle dog and cynomolgus monkey serum.

Authors:  P A Bombardt; J E Brewer; M G Johnson
Journal:  J Pharmacol Exp Ther       Date:  1994-04       Impact factor: 4.030

View more
  8 in total

1.  Determination of drug binding to plasma proteins using competitive equilibrium binding to dextran-coated charcoal.

Authors:  Leonid M Berezhkovskiy
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-07-14       Impact factor: 2.745

2.  Interpreting physicochemical experimental data sets.

Authors:  Nicola Colclough; Mark C Wenlock
Journal:  J Comput Aided Mol Des       Date:  2015-06-09       Impact factor: 3.686

3.  Irreversible binding of an anticancer compound (BI-94) to plasma proteins.

Authors:  Nagsen Gautam; Rhishikesh Thakare; Sandeep Rana; Amarnath Natarajan; Yazen Alnouti
Journal:  Xenobiotica       Date:  2015-04-14       Impact factor: 1.908

4.  PET Imaging of the AT1 receptor with [11C]KR31173.

Authors:  Tamas G Zober; William B Mathews; Esen Seckin; Sung-Eun Yoo; John Hilton; Jinsong Xia; Kathryn Sandberg; Hayden T Ravert; Robert F Dannals; Zsolt Szabo
Journal:  Nucl Med Biol       Date:  2006-01       Impact factor: 2.408

5.  Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics.

Authors:  J X Mazoit; K Samii
Journal:  Br J Clin Pharmacol       Date:  1999-01       Impact factor: 4.335

6.  Pharmacokinetics, protein binding and metabolism of a quinoxaline urea analog as an NF-κB inhibitor in mice and rats by LC-MS/MS.

Authors:  Nagsen Gautam; Sai Praneeth R Bathena; Qianyi Chen; Amarnath Natarajan; Yazen Alnouti
Journal:  Biomed Chromatogr       Date:  2013-03-10       Impact factor: 1.902

7.  Modulation of nonspecific binding in ultrafiltration protein binding studies.

Authors:  Kyoung-Jin Lee; Rachel Mower; Tom Hollenbeck; Jesus Castelo; Nikole Johnson; Perry Gordon; Patrick J Sinko; Kevin Holme; Yong-Hee Lee
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

8.  Evaluation of the Pharmacokinetics of the Pancreastatin Inhibitor PSTi8 Peptide in Rats: Integration of In Vitro and In Vivo Findings.

Authors:  Guru R Valicherla; Roshan A Katekar; Shailesh Dadge; Mohammed Riyazuddin; Anees A Syed; Sandeep K Singh; Athar Husain; Muhammad Wahajuddin; Jiaur R Gayen
Journal:  Molecules       Date:  2022-01-06       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.